{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-056101","form_type":"8-K","ticker":"BBWI","cik":"0000701985","company_name":"Bath & Body Works, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.406557+00:00","generated_at":"2026-06-26T00:05:49.544445+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CEO Andrew Meslow to depart May 12; receives $7M severance, extended non-compete","bullets":["CEO Andrew M. Meslow resigns effective May 12, 2022 due to health reasons.","Severance: $7 million cash over 24 months plus health coverage for 24 months.","Non-compete extended to 24 months globally; unvested equity forfeited (86k options, 123k RSUs, 1.3M PSUs).","Transition agreement unanimously approved by Board; Meslow agrees to cooperate and release claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-056101","json":"https://secwatch.observer/filing/0001104659-22-056101.json","markdown":"https://secwatch.observer/filing/0001104659-22-056101.md","text":"https://secwatch.observer/filing/0001104659-22-056101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/701985/000110465922056101/0001104659-22-056101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/701985/000110465922056101/tm228755d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:05:49.544445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c2d8254c1","claim":"Andrew M. Meslow departed as Chief Executive Officer at Bath & Body Works, Inc..","evidence_excerpt":"On May 4, 2022, Andrew M. Meslow, Chief Executive Officer of Bath & Body Works, Inc. (the “Company”) and a member of the Company’s Board of Directors (the “Board”), entered into a Transition and General Release Agreement (the “Transition and Release Agreement”) with the Company, in anticipation of his previously announced departure due to health reasons effective on May 12, 2022 (the “Separation Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/701985/000110465922056101/0001104659-22-056101-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}